Masimo has reported that the American Medical Association (AMA) has granted a new Current Procedural Terminology (CPT) code, 88738, for its noninvasive hemoglobin (SpHb) measurement. Medicare has priced the CPT code at $7.19 on the 2010 Medicare Clinical Laboratory Fee Schedule, effective January 1, 2010.

The company claims that new CPT code and pricing will allow healthcare providers to bill and receive payment when testing eligible patients. It has developed monitoring technologies that improve patient care. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events.

More than 100 independent and objective studies demonstrate Masimo SET provides a reliable SpO2 and pulse rate measurements under the challenging clinical conditions, including patient motion and low peripheral perfusion, said the company.

In 2005, the company has introduced Masimo Rainbow SET Pulse CO-Oximetry, a noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures.

Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), PVI, and acoustic respiration rate (RRa), oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions.